Skip to main content

Table 5 Summary of findings for secondary outcomes

From: Corticosteroid plus β2-agonist in a single inhaler as reliever therapy in intermittent and mild asthma: a proof-of-concept systematic review and meta-analysis

Comparisons

Nocturnal awakenings (no.)

Symptom-free days (%)

No. of Studies

SMD

95% CI

P value

I2-squared (%)

Power

No. of Studies

SMD

95% CI

P value

I2-squared (%)

Power

ICS/FABA regimen vs. FABA regimen

 All

2 [17, 30]

−0.290

[−0.490, −0.090]

0.004

8.7

0.96

4 [17, 27, 29, 30]

0.083

[−0.074, 0.240]

0.303

22.9

0.94

 Adult

1 [17]

−0.207

[−0.461, 0.047]

0.110

–

0.48

2 [17, 27]

0.068

[−0.147, 0.284]

0.534

0.0

0.16

 Children and adolescent

1 [30]

−0.427

[−0.752, −0.102]

0.010

–

0.82

2 [29, 30]

0.099

[−0.131, 0.329]

0.398

71.0

0.94

ICS/FABA regimen vs. ICS regimen

 All

2 [17, 30]

−0.098

[−0.284, 0.087]

0.299

0.0

0.57

4 [17, 26, 29, 30]

−0.253

[−0.373, −0.132]

<0.001

0.0

0.81

 Adult

1 [17]

−0.026

[−0.286, 0.234]

0.845

–

0.07

1 [17]

−0.160

[−0.421, 0.100]

0.228

–

0.32

 Children and adolescent

1 [30]

−0.173

[−0.438, 0.091]

0.200

–

0.36

3 [26, 29, 30]

−0.278

[−0.414, −0.142]

<0.001

0.0

0.66

ICS regimen vs. FABA regimen

 All

2 [17, 30]

−0.261

[−0.465, −0.056]

0.012

0.0

0.96

3 [17, 29, 30]

0.275

[0.102, 0.448]

0.002

0.0

1.00

 Adult

1 [17]

−0.212

[−0.475, 0.051]

0.115

–

0.47

1 [17]

0.249

[−0.015, 0.512]

0.064

–

0.56

 Children and adolescent

1 [30]

−0.335

[−0.658, −0.011]

0.043

–

0.64

2 [29, 30]

0.295

[0.065, 0.525]

0.012

40.8

0.99

Comparisons

Rescue medication required per day

FEV1% of predicted value

No. of Studies

SMD

95% CI

P value

I2-squared (%)

Power

No. of Studies

SMD

95% CI

P value

I2-squared (%)

Power

ICS/FABA regimen vs. FABA regimen

 All

5 [17, 27,28,29,30]

−0.138

[−0.290, 0.014]

0.076

18.0

0.98

3 [17, 27, 29]

0.773

[0.105, 1.441]

0.023

91.3

1.00

 Adult

3 [17, 27, 28]

−0.226

[−0.429, −0.023]

0.029

0.0

0.52

2 [17, 27]

0.405

[0.188, 0.623]

<0.001

0.0

0.94

 Children and adolescent

2 [29, 30]

−0.025

[−0.254, 0.205]

0.834

46.0

0.34

1 [29]

1.429

[1.064, 1.794]

<0.001

–

1.00

ICS/FABA regimen vs. ICS regimen

 All

5 [17, 26, 28,29,30]

0.192

[0.075, 0.309]

0.001

16.2

1.00

2 [17, 29]

−0.061

[−0.629, 0.506]

0.832

86.3

0.96

 Adult

2 [17, 28]

0.097

[−0.141, 0.335]

0.424

0.0

0.20

1 [17]

0.219

[−0.042, 0.480]

0.100

–

0.50

 Children and adolescent

3 [26, 29, 30]

0.222

[0.088, 0.356]

0.001

49.5

0.91

1 [29]

−0.360

[−0.691, −0.030]

0.033

–

0.68

ICS regimen vs. FABA regimen

 All

4 [17, 28,29,30]

−0.152

[−0.318, 0.014]

0.073

0.0

0.87

2 [17, 29]

0.415

[−0.102, 0.933]

0.001

83.2

1.00

 Adult

2 [17, 28]

−0.227

[−0.468, 0.014]

0.065

0.0

0.56

1 [17]

0.161

[−0.101, 0.424]

0.229

–

0.33

 Children and adolescent

2 [29, 30]

−0.084

[−0.313, 0.014]

0.471

55.1

0.53

1 [29]

0.690

[0.356, 1.024]

<0.001

–

0.99

  1. no. number, SMD standardized mean difference, CI confidence interval, ICS inhaled corticosteroids, FABA fast-onset-acting β2-agonist, ICS/FABA inhaled corticosteroids/fast-onset-acting β2-agonist
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us